OBJECTIVE: To evaluate treatment outcome of acute hepatitis C virus (HCV) in HIV-positive individuals. DESIGN: Open-label, prospective study conducted in London, January 1997-December 2003. METHODS: Patients in whom acute HCV infection had been diagnosed had sequential HCV RNA levels measured at 0, 4, 12, 24, 32, and 48 weeks. If HCV RNA positive at 12 weeks, patients were offered pegylated interferon alpha-2b 1.5 microg/kg/wk and ribavirin 800-1200 mg/d for 24 weeks. Patients with increasing HCV RNA titers were offered treatment earlier. RESULTS:Fifty male homosexuals with a mean age 37 years were identified: 44 from abnormal liver function test results, 4 from sexual contact with an HCV-positive partner, and 2 at HIV seroconversion. Overall, 12 individuals became HCV RNA negative spontaneously. This was significantly associated with high baseline median CD4(+) count (P = 0.029), CD4(+) count >500 cells/mm(3) (P = 0.017), and lower HCV RNA titers (P = 0.017). Only 27 patients accepted treatment, 16 (59%) of whom reached sustained virologic response. This was associated with higher peak mean alanine aminotransferase (P < 0.001) and higher baseline CD4% (P = 0.041). CONCLUSIONS:Sustained virologic response rates in HIV-positive patients treated for acute HCV infection are lower than in HIV-negative subjects. Because a high percentage of individuals seroconvert spontaneously, treatment should be delayed until after 12 weeks.
RCT Entities:
OBJECTIVE: To evaluate treatment outcome of acute hepatitis C virus (HCV) in HIV-positive individuals. DESIGN: Open-label, prospective study conducted in London, January 1997-December 2003. METHODS:Patients in whom acute HCV infection had been diagnosed had sequential HCV RNA levels measured at 0, 4, 12, 24, 32, and 48 weeks. If HCV RNA positive at 12 weeks, patients were offered pegylated interferon alpha-2b 1.5 microg/kg/wk and ribavirin 800-1200 mg/d for 24 weeks. Patients with increasing HCV RNA titers were offered treatment earlier. RESULTS: Fifty male homosexuals with a mean age 37 years were identified: 44 from abnormal liver function test results, 4 from sexual contact with an HCV-positive partner, and 2 at HIV seroconversion. Overall, 12 individuals became HCV RNA negative spontaneously. This was significantly associated with high baseline median CD4(+) count (P = 0.029), CD4(+) count >500 cells/mm(3) (P = 0.017), and lower HCV RNA titers (P = 0.017). Only 27 patients accepted treatment, 16 (59%) of whom reached sustained virologic response. This was associated with higher peak mean alanine aminotransferase (P < 0.001) and higher baseline CD4% (P = 0.041). CONCLUSIONS: Sustained virologic response rates in HIV-positive patients treated for acute HCV infection are lower than in HIV-negative subjects. Because a high percentage of individuals seroconvert spontaneously, treatment should be delayed until after 12 weeks.
Authors: G V Matthews; S T Pham; M Hellard; J Grebely; L Zhang; A Oon; P Marks; I van Beek; W Rawlinson; J M Kaldor; A Lloyd; G J Dore; P A White Journal: Clin Infect Dis Date: 2011-01-31 Impact factor: 9.079
Authors: Lynn E Taylor; Marisa Holubar; Kunling Wu; Ronald J Bosch; David L Wyles; John A Davis; Kenneth H Mayer; Kenneth E Sherman; Karen T Tashima Journal: Clin Infect Dis Date: 2011-01-31 Impact factor: 9.079
Authors: Emma C Thomson; Eleni Nastouli; Janice Main; Peter Karayiannis; Joseph Eliahoo; David Muir; Myra O McClure Journal: AIDS Date: 2009-01-02 Impact factor: 4.177
Authors: J M Turner; A T Rider; J Imrie; A J Copas; S G Edwards; J P Dodds; J M Stephenson Journal: Sex Transm Infect Date: 2006-08 Impact factor: 3.519
Authors: Christoph Boesecke; Patrick Ingiliz; Thomas Reiberger; Hans-Jürgen Stellbrink; Sanjay Bhagani; Emma Page; Stefan Mauss; Thomas Lutz; Esther Voigt; Marguerite Guiguet; Marc-Antoine Valantin; Axel Baumgarten; Mark Nelson; Martin Vogel; Jürgen K Rockstroh Journal: Infection Date: 2016-02 Impact factor: 3.553
Authors: Gregory J Dore; Margaret Hellard; Gail V Matthews; Jason Grebely; Paul S Haber; Kathy Petoumenos; Barbara Yeung; Philippa Marks; Ingrid van Beek; Geoffrey McCaughan; Peter White; Rosemary French; William Rawlinson; Andrew R Lloyd; John M Kaldor Journal: Gastroenterology Date: 2009-09-24 Impact factor: 22.682